MCRPC: add-on custirsen fails phase 3 AFFINITY trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Custirsen fails to boost survival in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after treatment with docetaxel.

Why this matters

  • Custirsen blocks protein clusterin, which is associated with treatment resistance. 
  • Pos...